Baxter BioPharma to provide fill/finish services for Moderna vaccine

By The Science Advisory Board staff writers

March 8, 2021 -- Baxter BioPharma has entered into an agreement with Moderna to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021.

Baxter is a contract manufacturing organization that specializes in parenteral (injected) pharmaceuticals, including vaccines. The manufacturing of Moderna's messenger RNA (mRNA)-based vaccine will take place at Baxter's fill/finish sterile manufacturing facilities located in Bloomington, IN. The site has capabilities and expertise in injectable delivery systems and clinical and commercial vaccine manufacturing.

Financial details of the agreement were not disclosed.

Moderna addresses SARS-CoV-2 variants, ramps up vaccine production
Moderna is pursuing two strategies against emerging SARS-CoV-2 variants. The company is evaluating booster vaccine doses and is increasing vaccine manufacturing...
U.S. commits to additional 100M Moderna COVID-19 vaccine doses
The U.S. government has purchased an additional 100 million doses of Moderna's COVID-19 vaccine.
U.S. increases order of Moderna mRNA COVID-19 vaccine to 300M doses
Moderna is in discussion with the U.S. government for the purchase of an additional 100 million doses of its messenger RNA (mRNA) COVID-19 vaccine,...
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter